Irinotecan: A review of the initial phase I trials

ONCOLOGY

Volumn 12, Issue 8 SUPPL., 1998, Pages 31-38

  Gail Eckhardt, S ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; DIPHENHYDRAMINE; GROWTH FACTOR; IRINOTECAN; LOPERAMIDE; ONDANSETRON;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; FRANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LEUKEMIA; LYMPHOMA; NEUTROPENIA; PHARMACODYNAMICS; SUBCUTANEOUS DRUG ADMINISTRATION; UNITED STATES; VOMITING;

EID: 13144304341     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Taguchi T, Wakui A, Hasegawa K: Phase I clinical study of CPT-11. Jpn J Chemother 17:115-120, 1990.
2. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210-221, 1995.
3. Merrouche Y, Extra JM, Abigerges D, et al: High-dose intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol 15(3):1080-1086, 1997.
4. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994.
5. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83(16):1164-1165, 1991.
6. de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994.
7. Rothenberg ML, Kuhn JG, Burris HA, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11):2194-2204, 1993.
8. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84(12): 972-973, 1992.
9. Catimel G, Chabot GG, Guastalla JP, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995.
10. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 8 (11):1907-1912, 1990.